Medicus Pharma Ltd.MDCX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · medicuspharma.com
Clinical-stage life-sciences company advancing SkinJect, a dissolvable microneedle patch for basal cell carcinoma, and Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer, through Phase 2 studies.
Key ratios
ROA
-278.1%TTM
2025
-204.1%2024
-185.4%2023
-256.2%
ROE
-2865.2%TTM
2025
-2981.2%2024
-525.4%
Recent news
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Medicus Pharma Receives UAE Department of Health Authorization for Precision Medicine Study Evaluating Teverelix in Women with Endometriosis
Medicus Pharma Receives FDA "Study May Proceed" Letter for NDA-Enabling Registrational SkinJect Study in Patients with Gorlin Syndrome
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Track MDCX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer